Collaboration and Research Arrangements |
6 Months Ended |
|---|---|
Jun. 30, 2024 | |
| Collaborative Arrangement Disclosure [Abstract] | |
| Collaboration and Research Arrangements |
3. Collaboration and Research Arrangements During the three and six months ended June 30, 2023, the Company recognized revenue of $2.8 million and $5.8 million, respectively, under a license and collaboration agreement with Global Therapeutics, Inc, now a subsidiary of Pfizer. As of June 30, 2023, the Company had deferred revenue outstanding under that agreement of approximately $2.2 million, all of which is classified as deferred revenue, current portion on the Company’s condensed consolidated balance sheet. As the agreement was terminated in October 2023, no revenue was recognized during the three and six month periods ended June 30, 2024. |
| X | ||||||||||
- Definition Collaborative Arrangement Disclosure [Abstract]. No definition available.
|
| X | ||||||||||
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|